Clinical Scorecard: Mild metabolic profile may mask MASLD risk
At a Glance
| Category | Detail |
|---|---|
| Condition | Metabolic dysfunction-associated steatotic liver disease (MASLD) |
| Key Mechanisms | Distinct genetic profiles and disease trajectories among subgroups |
| Target Population | Patients with MASLD |
| Care Setting | Clinical research and genetic analysis |
Key Highlights
- Five reproducible subgroups of MASLD identified with distinct characteristics
- Polygenic subgroup (C4) shows mild metabolic profile but significant liver risk
- C2 and C3 exhibit heterogeneous metabolic profiles
- C5 has elevated long-term risks of fibrosis and cirrhosis
- Integration of clinical and genetic data may enhance MASLD management
Guideline-Based Recommendations
Diagnosis
- Utilize latent class analysis of clinical and demographic variables for subgroup classification
Management
- Individualized clinical management based on genetic and metabolic risk profiles
Monitoring & Follow-up
- Longitudinal monitoring of liver-related outcomes in MASLD patients
Risks
- Increased likelihood of liver transplantation in polygenic subgroup C4
Patient & Prescribing Data
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
Subgroup C4 has low incidence of metabolic comorbidities but high liver-specific risks
Clinical Best Practices
- Consider genetic risk factors in the management of MASLD
- Monitor for liver complications in patients with mild metabolic profiles
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
